Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer

Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is clinically effective in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, the use of this treatment is limited by its high cost. A cost-effectiveness analysis of diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenqian, Qian, Lei, Li, Wei, Chen, Xiao, He, Hua, Tian, Huimin, Zhao, Yuguang, Wang, Xu, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903425/
https://www.ncbi.nlm.nih.gov/pubmed/33732316
http://dx.doi.org/10.3892/etm.2021.9774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903425/
https://www.ncbi.nlm.nih.gov/pubmed/33732316
http://dx.doi.org/10.3892/etm.2021.9774

Ejemplares similares